Healthcare, Pharma, Medical Device etc.
Category
Japan, United states of America, Europe, Rest of World
Geographic Coverage
Not Available
Video URL
Not Available
Sale price (USD)
Not Available
Non-exclusive license price (USD)
Not Available
Exclusive license price (USD)
Not Available
Non-exclusive license royalty rate %
Availability
Plus or Premium required
IP number
Plus or Premium required
Patent family
Plus or Premium required
Number of members in the patent family
Plus or Premium required
Applicant(s)
Plus or Premium required
Inventor(s)
Plus or Premium required
Assignee(s) / Patent owner(s)
Plus or Premium required
Priority date
Plus or Premium required
Application date
Plus or Premium required
Grant Date
Plus or Premium required
IPC / #
Plus or Premium required
CPC
Plus or Premium required
USPC
Plus or Premium required
Link to patent publication
To see the additional information details please login and subscribe to a Premium account.

Anti-CD22 antibodies

Patent Granted An anti-CD22 immunotoxin is a monoclonal antibody (targeting CD22) linked to a cytotoxic agent. They are being studied in the treatment of some types of B-cell cancer. They bind to CD22, a receptor protein on the surface of normal B cells and B-cell tumors, and, upon internalization, kill the cells.

MAKE AN OFFER
GET LICENSE BROKER APPLY submit an inquiry
photo To see the additional information details please login and subscribe to a Plus or Premium account.

Related IPs